Design and optimization of mefloquine hydrochloride microparticles for bitter taste masking.
The objective of the present investigation was to reduce the bitterness with improved dissolution, in acidic medium (pH 1.2), of mefloquine hydrochloride (MFL). Microparticles were prepared by coacervation method using Eudragit E (EE) as polymer and sodium hydroxide as precipitant. A 3(2) full factorial design was used for optimization wherein the drug concentration (A) and polymer concentration (B) were selected as independent variables and the bitterness score, particle size and dissolution at various pH were selected as the dependent variables. The desirability function approach has been employed in order to find the best compromise between the different experimental responses. The model is further cross validated for bias. The optimized microparticles were characterized by FT-IR, DSC, XRPD and SEM. Bitterness score was evaluated by human gustatory sensation test. Multiple linear regression analysis revealed that the reduced bitterness of MFL can be obtained by controlling the dissolution of microparticles at pH 6.8 and increasing the EE concentration. The increase in polymer concentration leads to reduction in dissolution of microparticles at pH > 5 due to its insolubility. However the dissolution studies at pH 1.2 demonstrated enhanced dissolution of MFL from microparticles might be due to the high porosity of the microparticles, hydrophilic nature of the EE, and improved wettability, provided by the dissolved EE. The bitterness score of microparticles was decreased to zero compared to 3+ of pure ARM. In conclusion the bitterness of MFL was reduced with improved dissolution at acidic pH.
Shah
Punit P
PP
Center of Relevance and Excellence in NDDS, Pharmacy Department, The M. S. University of Baroda, G H Patel building, Donor's Plaza, Fatehgunj, Vadodara, Gujarat, India. punitpshah@gmail.com
Mashru
Rajashree C
RC
Rane
Yogesh M
YM
Thakkar
Arti
A
D000284:Administration, Oral; D000962:Antimalarials / Q000008:administration & dosage* / Q000138:chemical synthesis* / Q000737:chemistry; D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical; D018360:Crystallography, X-Ray; D004339:Drug Compounding; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D015767:Mefloquine / Q000008:administration & dosage* / Q000138:chemical synthesis* / Q000737:chemistry; D008689:Methacrylates / Q000737:chemistry; D008768:Methylmethacrylates; D008855:Microscopy, Electron, Scanning; D008962:Models, Theoretical; D010316:Particle Size; D010470:Perceptual Masking; D016062:Porosity; D033362:Powder Diffraction; D015203:Reproducibility of Results; D012972:Sodium Hydroxide / Q000737:chemistry; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared; D013649:Taste; D013678:Technology, Pharmaceutical / Q000379:methods; D017155:Wettability
D000962:Antimalarials; D008689:Methacrylates; D008768:Methylmethacrylates; C102808:Eudragit-E; D012972:Sodium Hydroxide; D015767:Mefloquine